文献速递主动脉疾病

钝性胸主动脉损伤药物管理的结局与实践模式:主动脉创伤基金会全球登记研究

Outcomes and practice patterns of medical management of blunt thoracic aortic injury from the Aortic Trauma Foundation global registry.
PubMed 文献 · J Vasc Surg · 2021-09-21

基于主动脉创伤基金会国际前瞻性多中心登记,分析432例钝性胸主动脉损伤患者,其中114例以药物管理为计划确定性治疗;该策略在轻度损伤(1-2级)中安全有效,总体干预率低且无主动脉相关死亡。

要点

  • 约四分之一钝性胸主动脉损伤患者以药物管理作为确定性治疗。
  • 1-2级损伤药物管理安全有效,干预率低且无主动脉相关死亡。
  • 药物管理以β受体阻滞剂为主,目标收缩压多低于120 mmHg。

核心结论

  • 药物管理作为确定性治疗在轻度钝性胸主动脉损伤(1级和2级)中安全有效,支持对2级损伤采用确定性药物管理。

研究设计与样本

  • 主动脉创伤基金会国际前瞻性多中心登记研究,纳入2016年11月至2020年4月432例钝性胸主动脉损伤患者,分析其中114例以药物管理为计划确定性治疗者。

主要发现

  • 432例患者中245例(57%)初始接受药物管理,114例(26.4%)以药物管理为计划确定性治疗(1级59.6%、2级23.7%、3级15.8%、4级0.9%)。
  • 药物管理目标基于血压控制达到者占64.0%(73/114)。
  • 12例(10.5%)在药物管理后需后续干预,其中11例(9.6%)行胸主动脉腔内修复,1例(0.9%)因4级损伤行开放修复。
  • 选择确定性药物管理的患者总体院内死亡率为7.9%,无主动脉相关死亡。

关键数值与推荐

  • 药物管理使用持续可调输注降压药者占49.1%,间断弹丸注射者占29.8%,最常用药物为β受体阻滞剂(74.6%)。
  • 治疗以目标收缩压为导向者占83.3%,最常见目标为收缩压<120 mmHg(66.3%)。

临床怎么用

  • 对轻度钝性胸主动脉损伤(尤其是1级和2级)可考虑以药物管理作为确定性治疗,需控制血压并密切监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Blunt thoracic aortic injury (BTAI) is the second leading cause of death from blunt trauma. In the present study, we aimed to determine the outcomes of medical management (MM) for BTAI. We hypothesized from the results of several previously reported studies, that patients with a minimal aortic injury (BTAI grades 1 and 2) could safely be treated with definitive MM alone. METHODS: The Aortic Trauma Foundation international prospective multicenter registry was used to examine the demographics, injury characteristics, management, and outcomes of patients with BTAI. We analyzed a subset of patients for whom MM was initiated as definitive therapy. RESULTS: From November 2016 to April 2020, 432 patients (median age, 41 years; 76% male; median injury severity score, 34) with BTAI (Society for Vascular Surgery grade 1, 23.6%; grade 2, 14.4%; grade 3, 51.2%; grade 4, 10.9%) were evaluated. Of the 432 patients, 245 (57%) had received MM in the initial period and 114 (26.4%) had received MM as the planned definitive therapy (grade 1, 59.6%; grade 2, 23.7%; grade 3, 15.8%; grade 4, 0.9%). The most common mechanism of BTAI was a motor vehicle collision (60.4%). Hypotension was present on arrival in 74 patients (17.2%). Continuous titratable infusion of antihypertensive medication was used for 49.1%, followed by intermittent bolus administration (29.8%), with beta-blockers (74.6%) the most common agent used. Treatments were targeted to a goal systolic blood pressure for 83.3%, most often to a target goal systolic blood pressure <120 mm Hg (66.3%). The MM goals based on blood pressure control were attained in 64.0% (73 of 114). Twelve patients (10.5%; grade 1, 1; grade 2, 0; grade 3, 10; grade 4, 1) had required subsequent intervention after MM. Eleven patients (9.6%) had undergone thoracic endovascular aortic repair and one (0.9%) had required open repair for a grade 4 injury. The overall in-hospital mortality for patients selected for definitive MM was 7.9%. No aortic-related deaths had occurred in the patients receiving definitive MM. CONCLUSIONS: Approximately one in four patients with BTAI will receive MM as definitive therapy. The variation in the pharmacologic therapies used is considerable. MM for patients with minimal aortic injury (BTAI grades 1 and 2) is safe and effective, with a low overall intervention rate and no aortic-related deaths. These findings support the use of definitive MM for grade 2 BTAI.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Arbabi CN, DuBose J, Charlton-Ouw K, et al. Outcomes and practice patterns of medical management of blunt thoracic aortic injury from the Aortic Trauma Foundation global registry. J Vasc Surg. 2021. PMID: 34560220. doi:10.1016/j.jvs.2021.08.084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。